Cargando…

Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities

Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are complex and heterogeneous diseases characterized by a multifactorial etiology, therefore demanding a multimodal approach to disentangle the main pathophysiological components driving disease onset and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourgonje, Arno R., van Goor, Harry, Faber, Klaas Nico, Dijkstra, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371325/
https://www.ncbi.nlm.nih.gov/pubmed/36881831
http://dx.doi.org/10.14309/ctg.0000000000000579
_version_ 1785078123244552192
author Bourgonje, Arno R.
van Goor, Harry
Faber, Klaas Nico
Dijkstra, Gerard
author_facet Bourgonje, Arno R.
van Goor, Harry
Faber, Klaas Nico
Dijkstra, Gerard
author_sort Bourgonje, Arno R.
collection PubMed
description Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are complex and heterogeneous diseases characterized by a multifactorial etiology, therefore demanding a multimodal approach to disentangle the main pathophysiological components driving disease onset and progression. Adoption of a systems biology approach is increasingly advocated with the advent of multiomics profiling technologies, aiming to improve disease classification, to identify disease biomarkers, and to accelerate drug discovery for patients with IBD. However, clinical translation of multiomics-derived biomarker signatures is lagging behind because there are several obstacles that need to be addressed to realize clinically useful signatures. Multiomics integration and IBD-specific identification of molecular networks, standardization and clearly defined outcomes, strategies to tackle cohort heterogeneity, and external validation of multiomics-based signatures are critical aspects. While striving for personalized medicine in IBD, careful consideration of these aspects is, however, needed to adequately match biomarker targets (e.g., the gut microbiome, immunity, or oxidative stress) with their corresponding utilities (e.g., early disease detection and endoscopic and clinical outcome). Theory-driven disease classifications and predictions are still governing clinical practice, while this could be improved by adopting an unbiased, data-driven approach relying on molecular data structures integrated with patient and disease characteristics. In the foreseeable future, the main challenge will lie in the complexity and impracticality of implementing multiomics-based signatures into clinical practice. Still, this could be achieved by developing easy-to-use, robust, and cost-effective tools incorporating omics-derived predictive signatures and through the design and execution of prospective, longitudinal, biomarker-stratified clinical trials.
format Online
Article
Text
id pubmed-10371325
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-103713252023-07-27 Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities Bourgonje, Arno R. van Goor, Harry Faber, Klaas Nico Dijkstra, Gerard Clin Transl Gastroenterol Review Article Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are complex and heterogeneous diseases characterized by a multifactorial etiology, therefore demanding a multimodal approach to disentangle the main pathophysiological components driving disease onset and progression. Adoption of a systems biology approach is increasingly advocated with the advent of multiomics profiling technologies, aiming to improve disease classification, to identify disease biomarkers, and to accelerate drug discovery for patients with IBD. However, clinical translation of multiomics-derived biomarker signatures is lagging behind because there are several obstacles that need to be addressed to realize clinically useful signatures. Multiomics integration and IBD-specific identification of molecular networks, standardization and clearly defined outcomes, strategies to tackle cohort heterogeneity, and external validation of multiomics-based signatures are critical aspects. While striving for personalized medicine in IBD, careful consideration of these aspects is, however, needed to adequately match biomarker targets (e.g., the gut microbiome, immunity, or oxidative stress) with their corresponding utilities (e.g., early disease detection and endoscopic and clinical outcome). Theory-driven disease classifications and predictions are still governing clinical practice, while this could be improved by adopting an unbiased, data-driven approach relying on molecular data structures integrated with patient and disease characteristics. In the foreseeable future, the main challenge will lie in the complexity and impracticality of implementing multiomics-based signatures into clinical practice. Still, this could be achieved by developing easy-to-use, robust, and cost-effective tools incorporating omics-derived predictive signatures and through the design and execution of prospective, longitudinal, biomarker-stratified clinical trials. Wolters Kluwer 2023-03-07 /pmc/articles/PMC10371325/ /pubmed/36881831 http://dx.doi.org/10.14309/ctg.0000000000000579 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Bourgonje, Arno R.
van Goor, Harry
Faber, Klaas Nico
Dijkstra, Gerard
Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title_full Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title_fullStr Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title_full_unstemmed Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title_short Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
title_sort clinical value of multiomics-based biomarker signatures in inflammatory bowel diseases: challenges and opportunities
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371325/
https://www.ncbi.nlm.nih.gov/pubmed/36881831
http://dx.doi.org/10.14309/ctg.0000000000000579
work_keys_str_mv AT bourgonjearnor clinicalvalueofmultiomicsbasedbiomarkersignaturesininflammatoryboweldiseaseschallengesandopportunities
AT vangoorharry clinicalvalueofmultiomicsbasedbiomarkersignaturesininflammatoryboweldiseaseschallengesandopportunities
AT faberklaasnico clinicalvalueofmultiomicsbasedbiomarkersignaturesininflammatoryboweldiseaseschallengesandopportunities
AT dijkstragerard clinicalvalueofmultiomicsbasedbiomarkersignaturesininflammatoryboweldiseaseschallengesandopportunities